These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 10077639)

  • 1. Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53.
    Tao W; Levine AJ
    Proc Natl Acad Sci U S A; 1999 Mar; 96(6):3077-80. PubMed ID: 10077639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein.
    Roth J; Dobbelstein M; Freedman DA; Shenk T; Levine AJ
    EMBO J; 1998 Jan; 17(2):554-64. PubMed ID: 9430646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nuclear and cytoplasmic degradation of endogenous p53 and HDM2 occurs during down-regulation of the p53 response after multiple types of DNA damage.
    Joseph TW; Zaika A; Moll UM
    FASEB J; 2003 Sep; 17(12):1622-30. PubMed ID: 12958168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An intact HDM2 RING-finger domain is required for nuclear exclusion of p53.
    Boyd SD; Tsai KY; Jacks T
    Nat Cell Biol; 2000 Sep; 2(9):563-8. PubMed ID: 10980695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2.
    Tao W; Levine AJ
    Proc Natl Acad Sci U S A; 1999 Jun; 96(12):6937-41. PubMed ID: 10359817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hdmx recruitment into the nucleus by Hdm2 is essential for its ability to regulate p53 stability and transactivation.
    Migliorini D; Danovi D; Colombo E; Carbone R; Pelicci PG; Marine JC
    J Biol Chem; 2002 Mar; 277(9):7318-23. PubMed ID: 11744695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nucleocytoplasmic shuttling of p53 is essential for MDM2-mediated cytoplasmic degradation but not ubiquitination.
    O'Keefe K; Li H; Zhang Y
    Mol Cell Biol; 2003 Sep; 23(18):6396-405. PubMed ID: 12944468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6.
    Freedman DA; Levine AJ
    Mol Cell Biol; 1998 Dec; 18(12):7288-93. PubMed ID: 9819415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear degradation of p53 occurs during down-regulation of the p53 response after DNA damage.
    Shirangi TR; Zaika A; Moll UM
    FASEB J; 2002 Mar; 16(3):420-2. PubMed ID: 11790725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MEK-ERK signaling controls Hdm2 oncoprotein expression by regulating hdm2 mRNA export to the cytoplasm.
    Phelps M; Phillips A; Darley M; Blaydes JP
    J Biol Chem; 2005 Apr; 280(17):16651-8. PubMed ID: 15723837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation.
    Ghosh M; Huang K; Berberich SJ
    Biochemistry; 2003 Mar; 42(8):2291-9. PubMed ID: 12600196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway.
    Zhang Y; Wolf GW; Bhat K; Jin A; Allio T; Burkhart WA; Xiong Y
    Mol Cell Biol; 2003 Dec; 23(23):8902-12. PubMed ID: 14612427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53.
    Linares LK; Hengstermann A; Ciechanover A; Müller S; Scheffner M
    Proc Natl Acad Sci U S A; 2003 Oct; 100(21):12009-14. PubMed ID: 14507994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mono- versus polyubiquitination: differential control of p53 fate by Mdm2.
    Li M; Brooks CL; Wu-Baer F; Chen D; Baer R; Gu W
    Science; 2003 Dec; 302(5652):1972-5. PubMed ID: 14671306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cocompartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53.
    Xirodimas DP; Stephen CW; Lane DP
    Exp Cell Res; 2001 Oct; 270(1):66-77. PubMed ID: 11597128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abundant expression of spliced HDM2 in Hodgkin lymphoma cells does not interfere with p14(ARF) and p53 binding.
    Stürzenhofecker B; Schlott T; Quentin T; Kube D; Jung W; Trümper L
    Leuk Lymphoma; 2003 Sep; 44(9):1587-96. PubMed ID: 14565663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDM2 can promote the ubiquitination, nuclear export, and degradation of p53 in the absence of direct binding.
    Inoue T; Geyer RK; Howard D; Yu ZK; Maki CG
    J Biol Chem; 2001 Nov; 276(48):45255-60. PubMed ID: 11572869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The MDM2 RING-finger domain is required to promote p53 nuclear export.
    Geyer RK; Yu ZK; Maki CG
    Nat Cell Biol; 2000 Sep; 2(9):569-73. PubMed ID: 10980696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODs.
    Laín S; Midgley C; Sparks A; Lane EB; Lane DP
    Exp Cell Res; 1999 May; 248(2):457-72. PubMed ID: 10222137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear exclusion of p53 in a subset of tumors requires MDM2 function.
    Lu W; Pochampally R; Chen L; Traidej M; Wang Y; Chen J
    Oncogene; 2000 Jan; 19(2):232-40. PubMed ID: 10645001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.